Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 291 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Teclistamab ESMO Launches Clinical Trials Funding Initiative to Optimise Cancer Care Pathways FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid... September 30, 2022 Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once... September 26, 2024 Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy,... July 28, 2025 FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... March 8, 2024 Load more HOT NEWS Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar ESMO Launches Living Guidelines to Enhance the Usability of its Clinical... Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... It’s a fair COP: Why our chief clinician went to a...
